Compare Citius Pharmaceuticals Inc (CTXR) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lowe`s Companies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Lowe`s Companies Inc trades at $185.93 (market cap $105.96B). The key difference: Lowe`s Companies Inc is far larger — about 7779.7× Citius Pharmaceuticals Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Lowe`s Companies Inc for 98 Days on average.
| CTXR | LOW | |
|---|---|---|
Market Cap | $13.62M | $105.96B |
Volume | 132,438 | 4,039,547 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $287.39 |
52-Week Low | $0.48 | $179.50 |
Typical Hold Time | 17 Days | 98 Days |
Enterprise Value | $3.79M | $144.81B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Lowe's (LOW) trades at $185.27, up 2.05% today, but faces a bearish technical signal with key resistance at $191. The company reported Q2 2026 EPS of $4.40, beating estimates, yet revenue has declined from $96.2B in 2022 to $83.7B in 2025. Analysts maintain a strong buy consensus with a $244.09 price target, citing value despite industry headwinds. Recent news highlights drone delivery innovation with DoorDash and Alphabet's Wing, aiming to enhance customer convenience.
LOW presents a value opportunity with a P/E of 15.96 and bullish analyst sentiment, but risks include a challenging housing market and declining revenue trends. The stock's upside hinges on execution of new initiatives and economic recovery in home improvement spending, with near-term volatility expected amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
